JP2003529608A5 - - Google Patents

Download PDF

Info

Publication number
JP2003529608A5
JP2003529608A5 JP2001572544A JP2001572544A JP2003529608A5 JP 2003529608 A5 JP2003529608 A5 JP 2003529608A5 JP 2001572544 A JP2001572544 A JP 2001572544A JP 2001572544 A JP2001572544 A JP 2001572544A JP 2003529608 A5 JP2003529608 A5 JP 2003529608A5
Authority
JP
Japan
Prior art keywords
fusion protein
immunostimulatory
composition
protein
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2001572544A
Other languages
English (en)
Japanese (ja)
Other versions
JP5110674B2 (ja
JP2003529608A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2001/010515 external-priority patent/WO2001074855A2/en
Publication of JP2003529608A publication Critical patent/JP2003529608A/ja
Publication of JP2003529608A5 publication Critical patent/JP2003529608A5/ja
Application granted granted Critical
Publication of JP5110674B2 publication Critical patent/JP5110674B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP2001572544A 2000-03-30 2001-03-30 樹状細胞に基づく免疫治療のための組成物および方法 Expired - Fee Related JP5110674B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US19350400P 2000-03-30 2000-03-30
US60/193,504 2000-03-30
PCT/US2001/010515 WO2001074855A2 (en) 2000-03-30 2001-03-30 Compositions and methods for dendritic cell-based immunotherapy

Publications (3)

Publication Number Publication Date
JP2003529608A JP2003529608A (ja) 2003-10-07
JP2003529608A5 true JP2003529608A5 (enExample) 2008-05-22
JP5110674B2 JP5110674B2 (ja) 2012-12-26

Family

ID=22713907

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2001572544A Expired - Fee Related JP5110674B2 (ja) 2000-03-30 2001-03-30 樹状細胞に基づく免疫治療のための組成物および方法

Country Status (13)

Country Link
US (2) US7060279B2 (enExample)
EP (1) EP1272633B1 (enExample)
JP (1) JP5110674B2 (enExample)
AT (1) ATE507295T1 (enExample)
AU (2) AU4791901A (enExample)
CA (1) CA2403964C (enExample)
CY (1) CY1111718T1 (enExample)
DE (1) DE60144516D1 (enExample)
DK (1) DK1272633T3 (enExample)
ES (1) ES2362715T3 (enExample)
NZ (1) NZ522066A (enExample)
PT (1) PT1272633E (enExample)
WO (1) WO2001074855A2 (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7198920B1 (en) 1999-01-29 2007-04-03 Corika Corporation HER-2/neu fusion proteins
US7229623B1 (en) 2000-08-03 2007-06-12 Corixa Corporation Her-2/neu fusion proteins
US7413869B2 (en) * 2002-04-05 2008-08-19 Dendreon Corporation Method for determining potency of antigenic presenting cell based vaccines
MXPA04009809A (es) * 2002-04-11 2004-12-13 Amgen Inc Moleculas de tirosina cinasa del receptor her-2 y uso de las mismas.
CA2514288C (en) 2003-03-05 2015-07-07 Dendreon Corporation Compositions and methods employing alternative reading frame polypeptides for the treatment of cancer and infectious disease
US7737253B2 (en) * 2006-06-16 2010-06-15 Bresagen, Inc. Human cancer stem cell culture compositions comprising Erbb2 variants and methods of use thereof
US7972602B2 (en) * 2006-08-11 2011-07-05 Dendreon Corporation Promiscuous HER-2/Neu CD4 T cell epitopes
US20090181078A1 (en) 2006-09-26 2009-07-16 Infectious Disease Research Institute Vaccine composition containing synthetic adjuvant
AR064863A1 (es) * 2007-01-15 2009-04-29 Glaxosmithkline Biolog Sa Proteina de fusion
PL2118128T3 (pl) * 2007-01-15 2013-03-29 Glaxosmithkline Biologicals Sa Białka fuzyjne zawierające antygeny odrzucenia nowotworu NY-ESO-1 i LAGE-1
US8309096B2 (en) 2007-01-15 2012-11-13 Glaxosmithkline Biologicals S.A. Fusion protein
US8153120B2 (en) * 2007-03-22 2012-04-10 Dendreon Corporation Methods for inducing a natural killer (NK) cell-mediated immune response and for increasing NK cell activity
JP6426001B2 (ja) 2011-11-17 2018-11-21 グリア エスピー ゼット.オー.オー. 神経膠腫を治療するための組成物および方法
EP2777711A1 (en) * 2013-03-11 2014-09-17 Icon Genetics GmbH Her2/Neu cancer vaccine
WO2017096247A1 (en) 2015-12-04 2017-06-08 Mayo Foundation For Medical Education And Research Methods and vaccines for inducing immune responses to multiple different mhc molecules
TW202216776A (zh) 2020-07-07 2022-05-01 美商康愈有限責任公司 Mic抗體及結合劑以及其使用方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2048981B (en) * 1979-05-23 1982-11-17 Coal Ind Equipment for laying a layer of elongate material adjacent to an exposed rock or mineral surface in an underground mine
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
CA2158281A1 (en) * 1993-03-15 1994-09-29 Jay A. Berzofsky Peptide coated dendritic cells as immunogens
US5801005A (en) * 1993-03-17 1998-09-01 University Of Washington Immune reactivity to HER-2/neu protein for diagnosis of malignancies in which the HER-2/neu oncogene is associated
US5586538A (en) * 1995-11-13 1996-12-24 Caterpillar Inc. Method of correcting engine maps based on engine temperature
US6080409A (en) * 1995-12-28 2000-06-27 Dendreon Corporation Immunostimulatory method
WO1998046769A1 (en) * 1997-04-11 1998-10-22 Dendreon Corporation Composition and method for inducing an immune response against tumour-related antigens
US6194152B1 (en) * 1997-08-20 2001-02-27 Dendreon Corporation Prostate tumor polynucleotide compositions and methods of detection thereof
AU775767B2 (en) * 1998-12-14 2004-08-12 Dendreon Corporation Compositions and methods for enhancement of major histocompatibility complex class I restricted antigen presentation
CN1201004C (zh) * 1999-01-29 2005-05-11 考丽克萨有限公司 HER-2/neu融合蛋白
TR200103018T2 (tr) * 1999-04-19 2002-02-21 Beecham Biologicals S.A. Smithkline İmmünostimülatör oligonükleotid ve saponin içeren katkı bileşikleri.
US6406681B1 (en) * 2000-08-21 2002-06-18 Aeropharm Technology, Inc. Method of treating a systemic disease

Similar Documents

Publication Publication Date Title
JP2003529608A5 (enExample)
JP2004537252A5 (enExample)
DE69936784T2 (de) Behandlung von gebärmutterhalskrebs
CN110124018B (zh) 一种模拟坏死肿瘤细胞的磷酸钙-脂质纳米疫苗及其应用
JP2001512748A5 (enExample)
JP2003510366A5 (enExample)
CA2352783A1 (en) Stimulation of t cells against self antigens using ctla-4 blocking agents
JP2006526414A5 (enExample)
RU2012149618A (ru) Менингококковые полипептиды fhbp
CN1938044A (zh) 用于免疫治疗的基于酵母的疫苗
EP1567014A4 (en) ONE-STEP FAST PROCESS FOR PREPARING AN ANTIGEN-LOADED DENDRIT CELL VACCINE FROM PRE-STEP
JP2003521900A5 (enExample)
JP2005502314A5 (enExample)
WO2001023421A3 (en) Stress protein compositions and methods for prevention and treatment of cancer and infectious disease
JP2002534481A5 (enExample)
DE60319375D1 (de) Zweifach Coating-beschichteten Milchsäurenbakterienpulver mit Protein und Polysaccharid und das Verfahren zur deren Herstellung sowie deren Dosisform
JP2003530088A5 (enExample)
JP3059482B2 (ja) 大型多価免疫原
WO2019062853A1 (zh) 一种cd4辅助性t细胞表位融合肽及其疫苗
US20070164250A1 (en) Nanoparticle heating and applications thereof
JP2002522039A5 (enExample)
JP2004513615A5 (enExample)
EP1905449A3 (en) Adjuvant composition comprising saponin and an immunostimulatory oligonucleotide
JP2003519240A5 (enExample)
DE60227367D1 (de) Modifizierter granulozyten stimulierender factor (g-csf) mit verringerter immunogenität